Viatris Inc Q3 FY2026 results
$20.82+0.73%
Viatris Inc reported revenue of $3.75 billion, down 0.3% from a year earlier, net income of −$325 million and diluted earnings per share of −$0.28 against −$0.11 for the third quarter of fiscal 2026 (the three months to 30 Sep 2026).
From its quarterly report, filed 5 Nov 2026. Compiled and checked by AapWire.
Q3 FY2026 against Q3 FY2025
Three months to 30 Sep 2026, against the three months to 30 Sep 2025. Amounts in USD.
| Measure | Q3 FY2026 | Q3 FY2025 | Change |
|---|---|---|---|
| Revenue | $3.75B | $3.76B | −0.3% |
| Gross profit | $1.44B | $1.37B | +4.8% |
| Gross margin | 38.4% | 36.5% | +1.9 pts |
| Operating income | $261.5M | $178.8M | +46.3% |
| Operating margin | 7.0% | 4.8% | +2.2 pts |
| Net income | −$325.3M | — | — |
| Diluted EPS | −$0.28 | −$0.11 | — |
| Operating cash flow | $899.4M | $744.9M | +20.7% |
| Capital expenditure | $85.70M | $86.80M | −1.3% |
| Free cash flow | $813.7M | $658.1M | +23.6% |
Operating KPIs for the quarter
| KPI | Q3 FY2026 | Change on a year |
|---|---|---|
| Brands revenue | $2.5B | up 1.0% |
| Generics revenue | $1.3B | down 2.9% |
| Lipitor revenue | $451.9M | up 14.1% |
| Norvasc revenue | $190.2M | up 5.8% |
| EpiPen® Auto-Injectors revenue | $155.8M | down 0.9% |
| Lyrica ® revenue | $114.2M | down 9.7% |
| Creon ® revenue | $98.1M | up 5.4% |
| Viagra ® revenue | $94.1M | down 10.6% |
| Influvac ® revenue | $90.6M | down 27.8% |
| Zoloft ® revenue | $78.8M | up 18.0% |
| Yupelri ® revenue | $71.5M | up 0.1% |
| Celebrex ® revenue | $70.2M | down 4.2% |
| Effexor ® revenue | $63.9M | down 4.9% |
| Xalabrands revenue | $43.9M | up 13.7% |
| Xanax ® revenue | $36.6M | up 7.0% |
| Amitiza ® revenue | $36.4M | down 10.8% |
| Dymista ® revenue | $35.4M | up 4.7% |
| Developed Markets Segment revenue | $2.2B | down 1.8% |
| Greater China revenue | $702.6M | up 14.2% |
| Emerging Markets Segment revenue | $531.1M | down 7.1% |
Earlier quarters
| Quarter | Period end | Revenue | Change on a year | Diluted EPS |
|---|---|---|---|---|
| Q3 FY2026 | 30 Sep 2026 | $3.75B | −0.3% | −$0.28 |
| Q2 FY2026 | 30 Jun 2026 | $3.76B | +4.9% | −$0.10 |
| Q1 FY2026 | 31 Mar 2026 | $3.52B | +8.1% | $0.15 |
| Q4 FY2025 | 31 Dec 2025 | $3.70B | +5.0% | — |
| Q3 FY2025 | 30 Sep 2025 | $3.76B | +0.2% | −$0.11 |
| Q2 FY2025 | 30 Jun 2025 | $3.58B | −5.6% | $0.00 |
| Q1 FY2025 | 31 Mar 2025 | $3.25B | −11.2% | −$2.55 |
| Q4 FY2024 | 31 Dec 2024 | $3.53B | −8.1% | — |
More on Viatris Inc: financial statements · revenue · earnings per share
VTRS's results, as they are filed.
Releases read within minutes, guidance against results, the quarter in its eight-quarter history, and an alert on each new report.
